Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Core Insights - Cocrystal Pharma, Inc. reported positive safety and tolerability results from the Phase 1 study of CDI-988, a potent oral panviral protease inhibitor designed for norovirus and coronaviruses [1][2] - CDI-988 is positioned as a first-in-class oral treatment with a novel mechanism of action and broad-spectrum antiviral activity [2] - The Phase 1 study is being conducted in Australia, with participants receiving doses from 100 mg to 600 mg, and no serious adverse events were reported [2] Company Overview - Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing antiviral therapeutics targeting influenza viruses, coronaviruses, noroviruses, and hepatitis C viruses [5] - The company utilizes structure-based technologies and Nobel Prize-winning expertise to create innovative antiviral drugs [5] Norovirus Context - Noroviruses are highly contagious and responsible for an estimated 21 million cases of acute gastroenteritis annually in the U.S., leading to significant healthcare burdens [3] - The annual economic impact of noroviruses in the U.S. is estimated at $10.6 billion, with outbreaks commonly occurring in semi-closed communities [3] Coronavirus Context - Coronaviruses can cause a range of symptoms, from mild to severe, including pneumonia and acute respiratory distress syndrome [4] - Cocrystal aims to develop effective treatments for all coronaviruses, including SARS-CoV-2 and its variants, by targeting viral replication enzymes and proteases [4]